Fredun Pharmaceuticals MD and chairman
NSE: FREDUNBSE: 539730Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,365.50.
27 Oct: open ₹1,389.00, high ₹1,460.00, low ₹1,372.80
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,452 Cr1,474th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.82
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 18.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.80
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 61,67460.2% delivered
Fredun Pharmaceuticals' chairperson is DAULAT NARIMAN MEDHORA and its managing director FREDUN NARIMAN MEDHORA, as filed for the quarter to Jun 2026.
Fredun Pharmaceuticals board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonDAULAT NARIMAN MEDHORA
- Managing directorFREDUN NARIMAN MEDHORA
6 directors4 independent2 executive
- DAULAT NARIMAN MEDHORA · ChairpersonExecutive · joined Jun 1987 · 469 months as independent · 1 listed board · 1 committee seat
- FREDUN NARIMAN MEDHORA · Managing directorExecutive · joined Sep 2006 · 238 months as independent · 1 listed board · 1 committee seat
- POOJA NARENDRA SANGHAVIIndependent · joined Nov 2025 · 8 months as independent · 1 listed board · 1 as independent
- ANSHU GYAN AGARWALIndependent · joined Sep 2025 · 9 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- SONAL DHARMIN DESAIIndependent · joined Sep 2025 · 9 months as independent · 1 listed board · 1 as independent · 2 committee seats
- DAISY CYRIL DSOUZAIndependent · joined Nov 2023 · 32 months as independent · 2 listed boards · 2 as independent · 2 committee seats, 1 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
3 directors who left
- Aspi Raimalwala, left 29 Sep 2025: Tenure Completion
- Rohinton Kanga, left 29 Sep 2025: Tenure Completion
- Nariman Medhora, left 20 Jun 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 25 May 20266 of 6 present4 independent · 9 days in between
- 15 May 20266 of 6 present4 independent · 35 days in between
- 9 Apr 20266 of 6 present4 independent · 14 days in between
- 25 Mar 20266 of 6 present4 independent · 28 days in between
4 earlier meetings
- 24 Feb 20266 of 6 present4 independent · 9 days in between
- 14 Feb 20266 of 6 present4 independent · 4 days in between
- 9 Feb 20266 of 6 present4 independent · 25 days in between
- 14 Jan 20266 of 6 present4 independent
Audit Committee
Chair DAISY CYRIL DSOUZA
FREDUN NARIMAN MEDHORA, ANSHU GYAN AGARWAL, SONAL DHARMIN DESAI
- 25 May 20264 of 4 present3 independent · 9 days in between
- 15 May 20264 of 4 present3 independent · 89 days in between
- 14 Feb 20264 of 4 present3 independent · 4 days in between
- 9 Feb 20264 of 4 present3 independent
Nomination and remuneration committee
Chair SONAL DHARMIN DESAI
ANSHU GYAN AGARWAL, DAISY CYRIL DSOUZA
- 25 May 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair SONAL DHARMIN DESAI
DAISY CYRIL DSOUZA, ANSHU GYAN AGARWAL, DAULAT NARIMAN MEDHORA
- 25 May 20264 of 4 present3 independent
Risk Management Committee
Chair FREDUN NARIMAN MEDHORA
ANSHU GYAN AGARWAL, SONAL DHARMIN DESAI
- 25 May 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair SONAL DHARMIN DESAI
FREDUN NARIMAN MEDHORA, DAULAT NARIMAN MEDHORA, ANSHU GYAN AGARWAL
- 9 Feb 20264 of 4 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- R.H.Nisar & Co.Peer-review certificate valid to Sep 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesApr 2025, checked by Care Ratings Limited | 3.75 | – | – | No |